Updates on the Pharmacology of Antiretrovirals and DAAs
نویسنده
چکیده
17.7. Zeuzem S, Ghalib R, Rajender Reddy K, et al.Grazoprevir–elbasvir combination therapy for treatmentnaive cirrhotic and noncirrhotic patients with chronic HCVgenotype 1, 4, or 6 infection: a randomized trial. AnnIntern Med. Published online 24 April 2015doi:10.7326/M15-0785.8. Yeh WW. Drug-drug interactions withgrazoprevir/elbasvir: practical considerations for the careof HIV/HCV co-infected patients. 16th InternationalWorkshop on Clinical Pharmacology of HIV and HepatitisTherapy. 26-28 May 2015. Washington, DC. Invitedlecture.9. Desnoyer A, Pospai D, Lê MP, et al. Sofosbuvir inhaemodialysis: 400 mg daily or only the day ofhemodialysis? 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 26-28 May2015. Washington, DC. Abstract 19.10. Gandhi Y, Adamczyk R, Wang R, et al. Assessment ofdrug-drug interactions between daclatasvir anddarunavir/ritonavir or lopinavir/ritonavir. 16th InternationalWorkshop on Clinical Pharmacology of HIV and HepatitisTherapy. 26-28 May 2015. Washington, DC. Abstract 80.11. Tao X, Sims K, Hesney M, et al. The effect ofdaclatasvir, asunaprevir, and beclabuvir on thepharmacokinetics of selective serotonin reuptake inhibitors in healthy subjects. 16th International Workshop onClinical Pharmacology of HIV and Hepatitis Therapy. 26-28 May 2015. Washington, DC. Abstract 81.12. Bifano M, Hwang C, Oosterhuis B, et al. Assessmentof pharmacokinetic interactions of the HCV NS5Areplication complex inhibitor daclatasvir with antiretroviralagents: ritonavir-boosted atazanavir, efavirenz andtenofovir. Antivir Ther. 2013;18:931-940.13. Song I, Jerva F, Zong J, et al. Evaluation of druginteractions between dolutegravir and daclatasvir inhealthy subjects. 16th International Workshop on ClinicalPharmacology of HIV and Hepatitis Therapy. 26-28 May2015. Washington, DC. Abstract 79.14. Tafoya E, Lu Y, Luo M, et al. Population viral kineticmodeling: SVR prediction in HCV GT-3 cirrhotic patients with 24 weeks of daclatasvir + sofosbuvir administration.16th International Workshop on Clinical Pharmacology ofHIV and Hepatitis Therapy. 26-28 May 2015. Washington,DC. Abstract 3.15. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patientswith hepatitis C virus genotype 3 infection: ALLY-3 phaseIII study. Hepatology. 2015;61:1127-1135.16. Rower JE, Meissner EG, Jimmerson LC, et al.Pharmacokinetics of GS-331007 triphosphate in red bloodcells in HCV-infected subjects receiving sofosbuvir plusribavirin in the SPARE trial. 16th International Workshopon Clinical Pharmacology of HIV and Hepatitis Therapy.26-28 May 2015. Washington, DC. Abstract 8.17. Rower J, Hodara A, Tise S, et al. Intracellularpharmacokinetics of sofosbuvir in vivo. CROI 2015. February 23-26, 2015. Seattle, Washington. Abstract 81.18. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir andribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomizedclinical trial. JAMA. 2013;310:804-811.19. Kirby B, Ni L, Bekele N, Brainard DM, Kearney BP,Mathias A. Evaluation of PK/PD relationships betweenribavirin and sustained virologic response in HCV-genotype 3 infected subjects in the Sovaldi phase 3program. 16th International Workshop on ClinicalPharmacology of HIV and Hepatitis Therapy. 26-28 May2015. Washington, DC. Abstract 2.20. Younis I. Sensitivity of liver function classificationsystems for exposure changes. 16th InternationalWorkshop on Clinical Pharmacology of HIV and HepatitisTherapy. 26-28 May 2015. Washington, DC. Abstract 1. 21. Custodio J, Garner W, Callebaut C, et al. Thepharmacokinetics of tenofovir and tenofovir diphosphatefollowing administration of tenofovir alafenamide versustenofovir disoproxil fumarate. 16th International Workshopon Clinical Pharmacology of HIV and Hepatitis Therapy.26-28 May 2015. Washington, DC. Abstract 6.22. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamideversus tenofovir disoproxil fumarate, coformulated withelvitegravir, cobicistat, and emtricitabine, for initial
منابع مشابه
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
BACKGROUND Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million peop...
متن کاملOrigin, microbiology, nutrition, and pharmacology of D-amino acids.
Exposure of food proteins to certain processing conditions induces two major chemical changes: racemization of all L-amino acids (LAAs) to D-amino acids (DAAs) and concurrent formation of cross-linked amino acids such as lysinoalanine (LAL). The diet contains both processing-induced and naturally-formed DAA. The latter include those found in microorganisms, plants, and marine invertebrates. Rac...
متن کاملThe impact of upper alpha neurofeedback training on updates working memory in Kurdistan university girl students with academic burnout syndrome and depression symptom
This study was conducted to examine the impact of upper alpha neurofeedback training on updates working memory in Kurdistan university girl students with academic burnout syndrome and depression symptom. A semi experimental method designed with control and experimental groups, undergoing pre-test and post-test used. The subjects were selected from the Kurdistan university girl students in acad...
متن کاملI-36: Updates on Matching IVF Protocols with Patient Segments
Background - MaterialsAndMethods N;Results N;Conclusion N;
متن کاملSofosbuvir (Sovaldi) for the treatment of hepatitis C.
Hepatitis C (HCV) remains an important cause of chronic liver disease worldwide. Historically, treatment included pegylated-interferon and ribavirin with low efficacy and numerous side effects contributing to poor adherence and impairment of patients' well-being. The next step in developing better treatment regimens for HCV led to the development of the first-generation direct acting antivirals...
متن کاملWhy We Should Be Willing to Pay for Hepatitis C Treatment.
The launch of oral direct-acting antivirals (DAAs) to treat chronic hepatitis C virus (HCV) infection represents a significant shift in the HCV treatment paradigm. With DAAs, the sustained virologic response (SVR) (ie, efficacy of treatment) has increased to more than 90%, treatment duration has decreased to as few as 8 weeks, and these regimens have no major side effects. Coupled with the upda...
متن کامل